Is Inclisiran (Leqvio) The Next Big Thing For Treating Heart Disease?
At the very least, we do know that the patent profits will extend until at least 2035.
Leqvio is a “small interfering RNA (siRNA)-based therapeutic” that can “engage the endogenous RNA interference (RNAi) pathway to prevent the expression of select genes”.
In the case of Leqvio, it interferes with the expression of the proprotein convertase subtilsin/kexin type 9 (PCSK9) enzyme in the liver. The PCSK9 enzyme regulates the expression of low…
Keep reading with a 7-day free trial
Subscribe to The Biochemistry Of Human Health to keep reading this post and get 7 days of free access to the full post archives.